勃起不全：パイプライン分析

勃起不全(ED)とは、男性が性交渉に必要なだけの勃起を維持できない障害を指し、また性向不能症とも呼ばれています。疾病素質には血縁や体重過剰、傷害、麻薬・アルコール摂取、薬物療法（抗うつ剤・抗ヒスタミン剤・高血圧治療薬・鎮痛剤・前立腺がん治療薬ほか）などが含まれています。

当レポートでは、世界各国での勃起不全(ED)治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

• 分析範囲

勃起不全(ED)の概要

治療薬の開発

• 勃起不全向けパイプライン製品：概要
• 勃起不全向けパイプライン製品：比較分析

各企業で開発中の勃起不全治療薬

大学／研究機関で研究中の勃起不全治療薬

パイプライン製品の概略

• 後期段階の製品
• 治験段階の製品
• 初期段階の製品
• 不明確な段階にある製品

勃起不全治療薬：開発中の製品の一覧（企業別）

勃起不全治療薬：研究中の製品の一覧（大学／研究機関別）

勃起不全治療薬の開発に従事している企業

• Acorda Therapeutics, Inc.
• Apricus Biosciences, Inc.
• Biopharm GmbH
• Corridor Pharmaceuticals Inc.
• Futura Medical Plc
• Hanmi Pharmaceuticals, Co. Ltd.
• Humanetics Corporation
• IntelGenx Corp.
• Mezzion Pharma Co. Ltd.
• 田辺三菱製薬
• Monosol Rx, LLC
• NAL Pharmaceuticals Ltd.
• Pacific Therapeutics Ltd.
• Palatin Technologies, Inc.
• Pharmicell Co., Ltd.
• Sihuan Pharmaceutical Holdings Group Ltd.
• Suda Ltd
• U.S. Stem Cell, Inc.
• Yungjin Pharm. Co., Ltd.

勃起不全：治療薬の評価

• 単剤治療薬の場合
• 併用治療薬の場合
• 標的別
• 作用機序別
• 投与方法別
• 分子の種類別

薬剤のプロファイル

• (PDE-5 阻害剤 + 塩酸トラマドール)
  • 製品概要
  • 機能メカニズム
  • 研究開発(R&D)の進展状況
• AdipoCell
• alprostadil
• AP-102
• avanafil
• BIO-300
• BL-214
• cimaglermin alfa
• fadanafil
• HCP-1302
• HCP-1303
• Immpocellgram
• MED-2005
• ニトログリセリン
• 心血管疾患・代謝異常・勃起不全治療用 Gタンパク質共役受容体Mas活性ペプチド
• 変性円板疾患・骨折・パーキンソン病・勃起不全治療用合成タンパク質
• クエン酸シルデナフィル
• 血管機能不全・ PAH・勃起不全治療用アルギナーゼ阻害剤
• 勃起不全治療用 PDE5阻害薬
• SUD-003
• 女性の性機能障害・勃起不全治療用メラノコルチン4受容体作動合成ペプチド
• T-6932
• tadalafil
• TF-0092
• TPN-171
• TPN-729
• TR-399
• udenafil
• VLFIA-330
• YBH-1603

勃起不全治療薬：パイプライン製品の最新動向

勃起不全治療薬：開発が休止状態の製品

勃起不全治療薬：開発が中止された製品

勃起不全関連製品の開発のマイルストーン

• 注目すべき最新動向・プレスリリース
• ■付録

図表一覧

List of Tables

List of Tables

• Number of Products under Development for Erectile Dysfunction, H2 2020
• Number of Products under Development by Companies, H2 2020
• Number of Products under Development by Companies, H2 2020 (Contd..1), H2 2020
• Number of Products under Development by Universities/Institutes, H2 2020
• Products under Development by Companies, H2 2020
• Products under Development by Companies, H2 2020 (Contd..1), H2 2020
• Products under Development by Universities/Institutes, H2 2020
• Number of Products by Stage and Target, H2 2020
• Number of Products by Stage and Mechanism of Action, H2 2020
• Number of Products by Stage and Route of Administration, H2 2020
• Number of Products by Stage and Molecule Type, H2 2020
• Erectile Dysfunction - Pipeline by AnyGen Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Aprogen Inc, H2 2020
• Erectile Dysfunction - Pipeline by Aquestive Therapeutics Inc, H2 2020
• Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2020
• Erectile Dysfunction - Pipeline by Biozeus Pharmaceutical SA, H2 2020
• Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2020
• Erectile Dysfunction - Pipeline by CardioVascular BioTherapeutics Inc, H2 2020
• Erectile Dysfunction - Pipeline by Cure Pharmaceutical Inc, H2 2020
• Erectile Dysfunction - Pipeline by Dicot AB, H2 2020
• Erectile Dysfunction - Pipeline by Druggability Technologies Holdings Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Exopharm Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2020
• Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2020
• Erectile Dysfunction - Pipeline by Guangzhou Four-Leaf Clover HealthTech Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Hemostemix Inc, H2 2020
• Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2020
• Erectile Dysfunction - Pipeline by ILGEN Inc, H2 2020
• Erectile Dysfunction - Pipeline by Initiator Pharma AS, H2 2020
• Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2020
• Erectile Dysfunction - Pipeline by Klaria Pharma Holding AB, H2 2020
• Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by MicroCures Inc, H2 2020
• Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2020
• Erectile Dysfunction - Pipeline by MyX Therapeutics Inc, H2 2020
• Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Organicell Regenerative Medicine Inc, H2 2020
• Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Reven Pharmaceuticals Inc, H2 2020
• Erectile Dysfunction - Pipeline by Seelos Therapeutics, Inc., H2 2020
• Erectile Dysfunction - Pipeline by siRNAgen Therapeutics Corp, H2 2020
• Erectile Dysfunction - Pipeline by Suda Pharmaceuticals Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Targazyme Inc, H2 2020
• Erectile Dysfunction - Pipeline by Techfields Pharma Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Tritech Biopharmaceuticals Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Veru Inc, H2 2020
• Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2020
• Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2020
• Erectile Dysfunction - Dormant Projects, H2 2020
• Erectile Dysfunction - Dormant Projects, H2 2020 (Contd..1), H2 2020
• Erectile Dysfunction - Dormant Projects, H2 2020 (Contd..2), H2 2020
• Erectile Dysfunction - Discontinued Products, H2 2020

List of Figures

List of Figures

• Number of Products under Development for Erectile Dysfunction, H2 2020
• Number of Products under Development by Companies, H2 2020
• Number of Products under Development by Universities/Institutes, H2 2020
• Number of Products by Top 10 Targets, H2 2020
• Number of Products by Stage and Top 10 Targets, H2 2020
• Number of Products by Top 10 Mechanism of Actions, H2 2020
• Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
• Number of Products by Top 10 Routes of Administration, H2 2020
• Number of Products by Stage and Top 10 Routes of Administration, H2 2020
• Number of Products by Molecule Types, H2 2020
• Number of Products by Stage and Molecule Types, H2 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Pipeline Review, H2 2020, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 3, 6, 5, 14, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

• The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
• The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to Buy:

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

• Introduction
• Erectile Dysfunction - Overview
• Erectile Dysfunction - Therapeutics Development
• Erectile Dysfunction - Therapeutics Assessment
• Erectile Dysfunction - Companies Involved in Therapeutics Development
• Erectile Dysfunction - Drug Profiles
• Erectile Dysfunction - Dormant Projects
• Erectile Dysfunction - Discontinued Products
• Erectile Dysfunction - Product Development Milestones
• Appendix